High blood sugar leaves marks on the heart that outlast the sugar itself. A new review published in Clinical Epigenetics on 28 September 2026 argues that diabetic cardiomyopathy — injury to the heart muscle caused by diabetes — can persist even when metabolic control improves, and that current glycemic status alone cannot fully explain how the disease progresses.
The review, authored by Yuqing Huang, Qiming Gong, Yuling Yang, Yueli Pu, Jia Feng, Yu Li, Qifu Li, Xia Fang and Yong Xu, frames this persistence as “metabolic memory”: prior metabolic stress is retained through relatively stable epigenetic and transcriptional changes. In other words, episodes of high glucose, fat overload, insulin resistance and chronic inflammation appear to rewrite the regulatory layer that sits on top of the genome, and some of those rewrites survive after the original insult is gone.
According to the authors, recurrent hyperglycemia, lipotoxicity, insulin resistance and chronic inflammation reshape four broad classes of regulation: DNA methylation, histone modifications, chromatin accessibility and non-coding RNA control. Together these mechanisms determine which genes are switched on or off in heart cells without altering the underlying DNA sequence.
A central contribution of the review is a distinction the authors draw explicitly. Several molecular and regulatory alterations have been shown to persist after glycemic normalization or after the triggering stimulus is withdrawn, whereas others have been characterized only during ongoing diabetes or metabolic stress. For that second group, the review states, persistence after metabolic normalization remains unverified — a caveat that matters for how the metabolic memory concept is interpreted and tested.
The persistent programs described in the review sustain oxidative stress, mitochondrial dysfunction, inflammation, endothelial injury, fibrosis and abnormal intercellular communication within the diabetic heart. The authors integrate these findings across the main cell types of the heart, covering cardiomyocytes, endothelial cells, fibroblasts and immune cells, reflecting the view that metabolic memory is not confined to a single cell type.
On the therapeutic side, the review discusses four complementary categories of approach: metabolic modulation, epigenetic interventions, RNA-based strategies and targeted delivery. The authors position these as ways to reduce ongoing injury, prevent persistent regulatory programs from being established, improve diabetic cardiomyopathy during active diabetes, and potentially reverse residual abnormalities after metabolic normalization.
Importantly, the review is a synthesis of existing literature rather than a new clinical trial, and its therapeutic discussion is framed as potential rather than demonstrated. The stated aim is to extend treatment beyond current metabolic control to the persistent molecular consequences of prior metabolic injury — a shift from treating today’s glucose levels to addressing the regulatory imprint of yesterday’s.
The article is published open access and is currently shared as an accepted manuscript that is citable and carries a permanent DOI, subject to further edits before the final version of record. For researchers studying diabetic heart disease, the review’s key message is methodological as much as mechanistic: epigenetic changes observed during diabetes should not automatically be assumed to persist once glucose is controlled, and distinguishing truly persistent programs from diabetes-associated ones is essential for identifying which therapeutic reversal strategies are worth pursuing.
Subject of Research: Persistent epigenetic changes and potential therapeutic reversal strategies in diabetic cardiomyopathy
Article Title: Remodeling metabolic memory: persistent epigenetic injury and therapeutic reversal strategies in diabetic cardiomyopathy
Article References: Huang, Y., Gong, Q., Yang, Y., Pu, Y., Feng, J., Li, Y., Li, Q., Fang, X., & Xu, Y. (2026). Remodeling metabolic memory: persistent epigenetic injury and therapeutic reversal strategies in diabetic cardiomyopathy. Clinical Epigenetics. https://doi.org/10.1186/s13148-026-02236-4
Image Credits: AI Generated
DOI: 10.1186/s13148-026-02236-4
Keywords: diabetic cardiomyopathy, metabolic memory, epigenetics, DNA methylation, histone modifications, non-coding RNA, chromatin accessibility, hyperglycemia, lipotoxicity, fibrosis, mitochondrial dysfunction, review
News Source: Juliet Wilcox. (October 29, 2026). Epigenetic ‘metabolic memory’ may keep injuring the diabetic heart after blood sugar improves. Scienmag.
